llrx-royce.blogspot.com
Prostate cancer is the most commonj cancer diagnosedin men. Nearly 220,000 men were diagnosed with the diseasdlast year, according to the . Philip Sass, the Exton, Pa., biopharmaceuticak company's executive vice presidengt and chiefoperating officer, said the agreement adds to Morphetek'w existing collaborative relationship with NCI to develop novel therapiews to treat various types of cancer.
"Thse NCI brings significant expertise in the evaluatiojn and validation of lead antibodiesto cancer-specifidc proprietary targets," Sass said, "whicj complements Morphotek's expertise in the development of antibodies as potentiakl cancer treatments through biological and immunological Moprhotek is a subsidiarty of , a Japanese pharmaceutical It is developing treatments for cancer, rheumatoied arthritis, and infectious disease.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment